Batavia Biosciences

Batavia Biosciences announced last week that it has successfully manufactured shots for Phase 1 trials in Africa and the U.S. of the recombinant vesicular stomatitis virus (rVSV) vector-based Lassa fever vaccine being developed by the International AIDS Vaccine Initiative (IAVI).

The Dutch company, which initially partnered with IAVI in 2018, said it manufactured rVSVΔG-LASV-GPC using its HIP-Vax platform, which “enables the production of high volumes of vaccine doses in a small…

The state of the hunt:

The United Kingdom issued emergency authorization of Pfizer/BioNTech’s vaccine.
  WHO is reviewing the Pfizer/BioNTech shot for Emergency Use Listing.
  Moderna requested emergency nods for its mRNA-based vaccine from the U.S. FDA and the European Medicines Agency.



Approved or authorized vaccines

Pfizer is now seeking full British marketing authorization for its Covid-19 vaccine “in parallel” with the…

Batavia Biosciences and Valneva announced this week that they would work together to “accelerate market access” to a low-cost inactivated polio vaccine (IPV), according to a joint press release.

For an undisclosed upfront payment and monthly service fees, Valneva’s Swedish subsidiary will manufacture Sabin-based IPV using Batavia's low-cost HIP-VAX manufacturing process in combination with Univercells' NevoLine micro-facility technology. France’s Batavia will supply the…

Batavia Biosciences announced this week that the Gates Foundation is investing an additional $13.2 million to help the Dutch company advance low-cost polio vaccine manufacturing.

Batavia said the funds will enable it to use its optimized process and consortium partner Univercells’ NevoLine micro-facility platform to supply clinical-grade Sabin-based inactivated polio vaccine to developing country manufacturers and accelerate licensing of new vaccine products at less than $0.30 per dose…